

1 CETP inhibition Reduces Cardiovascular Events by 2 Lowering of Cumulative LDL Exposure: Reconciling 3 Evidence from Human Genetics and Clinical Trials

4
5 **Fredrik Landfors^{1,2,*}, John J.P. Kastelein^{3,4}, Elin Chorell¹**

6
7 ¹ Department of Public Health and Clinical Medicine, Section of Medicine, Umea
8 University, S-901 87 Umea, Sweden.

9 ² Lipigon Pharmaceuticals AB, S-907 36 Umea, Sweden.

10 ³ Department of Vascular Medicine, Academic Medical Center, University of Amsterdam,
11 the Netherlands

12 ⁴ NewAmsterdam Pharma, Naarden, the Netherlands

13

14 * To whom correspondence should be addressed.

15

16 **Contact information for the corresponding author:** Fredrik Landfors, Department of
17 Public Health and Clinical Medicine, Umea University, S-901 87 Umea, Sweden; Email:
18 Fredrik.Landfors@umu.se; Phone: +46 (0) 70-454 92 08.

19 Abstract

20 **Background:** Genetic studies consistently demonstrate that individuals born
21 with reduced Cholesteryl Ester Transfer Protein (CETP) activity experience lower rates of
22 atherosclerotic vascular disease throughout their lives. In contrast, short-term
23 randomized controlled trials of CETP inhibitors have yielded mixed results, with only one
24 of four trials reporting a reduction in clinical events. Several theories have been proposed
25 to explain this discrepancy, but none fully account for the central mechanism of
26 atherosclerosis: the cumulative lifetime exposure to circulating low-density lipoprotein
27 (LDL) particles in the arterial walls.

28 **Objectives:** We aimed to reconcile these conflicting findings by examining
29 the relationship between cumulative LDL exposure and atherosclerosis risk across both
30 genetic studies and clinical trials.

31 **Methods:** We analyzed 679 carriers of *CETP* protein-truncating variants
32 (resulting in reduced or non-functional CETP protein) and 505,837 non-carriers in a
33 population with 95,568 atherosclerosis events. Additionally, we assessed treatment
34 effects relative to cumulative LDL reductions in 34 cardiovascular prevention trials
35 involving 328,036 participants and 53,161 events.

36 **Results:** Heterozygous *CETP* protein-truncating variant carrier status
37 reduced atherosclerotic disease risk (odds ratio, 0.70; 95% confidence interval, 0.57–
38 0.85; $P=5\times 10^{-4}$). In clinical trials, we observed a significant interaction between the
39 magnitude and duration of LDL lowering on treatment effects (hazard ratio, 0.69 per 10–
40 mmol/L×years; 95% confidence interval, 0.52–0.90; $P=0.007$), supporting that reducing
41 cumulative LDL exposure is key to lowering cardiovascular risk. When comparing
42 genetics with trial outcomes, accounting for differences in timing, duration, and follow-
43 up, we observed consistent effects on atherosclerosis-related events per LDL years
44 across genetic and pharmacological CETP inhibition, as well as with statins, ezetimibe,
45 PCSK9 inhibitors, and familial hypercholesterolemia-associated variants (hazard ratio,
46 0.74 and 0.69 per 10–mmol/L×years, respectively). This suggests that CETP inhibition
47 reduces cardiovascular risk primarily through LDL. Notably, several trials failed to achieve
48 sufficient cumulative LDL reduction to impact clinical events, and this was not unique to
49 CETP inhibitors.

50 **Conclusion:** Our findings indicate that future CETP inhibitor trials achieving
51 substantial and sustained LDL reduction will demonstrate efficacy in preventing
52 cardiovascular events. These results highlight the importance of long-term LDL lowering
53 and support further investigation of CETP inhibition as a strategy for cardiovascular
54 prevention.

55

56 Introduction

57 Cholesteryl ester transfer protein (CETP) is a lipid exchange protein found in
58 the circulation of humans and certain higher mammals. It facilitates the transfer of
59 cholesteryl esters from high-density lipoprotein (HDL) to low-density (LDL) or very-low-
60 density lipoprotein (VLDL) in exchange for triglycerides^{1,2} Reduced CETP activity may
61 benefit human health by shifting plasma cholesterol from atherogenic LDL and VLDL to
62 HDL, decreasing the number of cholesterol-containing particles that can accumulate in
63 arterial walls, potentially slowing down atherosclerosis development.³⁻⁵ Several studies
64 also suggest CETP inhibition improves HDL functionality and promotes cholesterol efflux
65 from plaque macrophages, further mitigating atherogenesis.^{3,6,7} However, the precise
66 impact of CETP inhibition on atherosclerosis remains under investigation.

67 CETP's contribution to atherogenesis led to the development of CETP
68 inhibitors for atherosclerotic cardiovascular disease (ASCVD). Clinical trials of these
69 inhibitors, however, yielded mixed results. Torcetrapib, the first inhibitor, increased
70 cardiovascular events and mortality through off-target effects such as raised blood
71 pressure and aldosterone levels.^{8,9} Subsequent inhibitors, dalcetrapib and evacetrapib,
72 were safe but failed to reduce cardiovascular events in outcomes trials, possibly due to
73 insufficient LDL lowering and the short duration of the trials.¹⁰⁻¹² Anacetrapib showed
74 promise by reducing ASCVD events in a phase 3 trial, but its development was halted after
75 it was found to accumulate in adipose tissue, raising long-term safety concerns.^{13,14}
76 Obicetrapib, a less lipophilic yet potent CETP inhibitor, is currently being evaluated in
77 phase 3 trials.^{10,15} The single success among four major trials has cast doubt on CETP
78 inhibition's therapeutic value in atherosclerosis prevention.

79 Early atherosclerotic lesions begin forming in childhood, and cumulative
80 exposure to LDL drives the progression of ASCVD through plaque formation.^{16,17}
81 Therefore, evaluating the long-term effects of CETP inhibition requires considering the
82 duration and timing of LDL cholesterol (LDL-C) lowering. Human genetics offers a way to
83 assess the potential of such sustained CETP inhibition in preventing ASCVD. Genetic
84 variants that naturally reduce CETP activity from conception provide a “natural
85 experiment” to predict the long-term effects of CETP inhibition. By analyzing health
86 outcomes in individuals carrying protein-truncating variants (PTVs) in the *CETP* gene,

87 which lead to reduced or non-functional proteins, we can infer the impact of lifelong CETP
88 inhibition on ASCVD risk.¹⁸⁻²¹ This approach minimizes confounding and reverse
89 causation, and has proven effective in predicting drug target outcomes.^{22,23}

90 Given the potential of CETP inhibition and the conflicting results from clinical
91 trials, this study aimed to determine whether CETP inhibition reduces ASCVD risk by
92 lowering LDL particles. To ensure reliable long-term estimates, we analyzed the effects of
93 genetic CETP inhibition across diverse populations. Additionally, we tested the
94 cumulative LDL exposure hypothesis using clinical trial data. To reconcile the conflicting
95 findings on CETP inhibition, we introduce the concept of 'LDL-C Plaque Years,' which
96 models the cumulative impact of LDL-C reduction over time. This enabled a direct
97 comparison between lifelong genetic reductions and shorter-term pharmacological
98 effects from clinical trials. By accounting for differences in timing, duration, and
99 magnitude between genetic and clinical studies, we found that CETP inhibition lowers
100 ASCVD risk, but only when LDL-C is significantly reduced for a sustained period.

101 Methods

102 The analyses in this paper were conducted in two sequential steps. First, we measured
103 the impact of *CETP* PTVs on ASCVD risk in the UK Biobank and performed a meta-analysis
104 across diverse ancestries. Second, we assessed the plausibility of these genetic results
105 by comparing the effects of genetic and pharmacological *CETP* inhibition on ASCVD risk
106 relative to their cumulative LDL-C lowering, and against guideline-recommended lipid-
107 lowering therapies and *LDLR* PTVs (encoding the LDL receptor).

108 Step 1

109 Genetic association study of *CETP* protein-truncating variants and 110 atherosclerotic disease

111 *Study design and data sources*

112 The impact of lifetime *CETP* inhibition on ASCVD risk was measured in *CETP*
113 PTV carriers and non-carriers in the United Kingdom Biobank (UKB). The UKB is a
114 population-based study that has gathered a vast array of research data, including health
115 outcomes data, genetics, and blood chemistry from 500,000 participants across the
116 United Kingdom.²⁴ The study enrolled individuals aged 40-69 between 2006 and 2010,
117 during which blood samples were collected. Ongoing follow-up of these participants
118 ensures that their health information is continuously updated through medical records,
119 death certificates, and registries. The data (UKB v18.1) were released to us on January 14,
120 2024.

121 The primary outcome was ASCVD events (**TABLE 1** details the primary and
122 secondary endpoints). Diagnoses and event dates were retrieved from the first
123 occurrences data set (UKB data fields 131271–131423). ASCVD events were defined as
124 the first occurring hospital-record, death certificate, or primary care diagnosis of
125 coronary heart disease (ICD-10: I20-I25), ischemic stroke (I63), or peripheral
126 atherosclerosis (I70). We did not consider self-reported diagnoses as being positive for
127 an endpoint. Myocardial infarction was defined as being positive for ICD-10 codes I21–
128 I23. Cardiovascular death was defined as any atherosclerotic event (defined above) or
129 sudden cardiac death (I46.1) being recorded as the primary cause of the death in a death

130 certificate (UKB data field 40001). Major adverse cardiovascular events were defined as
131 the first-occurring stroke, myocardial infarction, or cardiovascular death.

132 Exposure to a defective *CETP* allele was assumed to begin at conception,
133 and participants were followed from their birth (UKB data fields 34, 54) until the
134 occurrence of the first event, loss to follow-up (UKB data field 191), death (UKB data field
135 40000), or the end of the study period (January 1, 2023), whichever occurred first.
136 Diabetes presence, statin medication, and smoking status were defined according to
137 their self-reported status at enrollment between the years 2006-2010 (UKB data fields
138 2443, 20003, 20116). LDL-C was measured both directly (UKB data field 30780), and
139 calculated using the Friedewald formula from total cholesterol, HDL, and triglycerides
140 (UKB data fields 30690, 30760, 30870). Non-HDL cholesterol was calculated by
141 subtracting HDL from total cholesterol, and remnant cholesterol was calculated by
142 subtracting directly measured LDL-C cholesterol from non-HDL cholesterol.
143 Apolipoprotein A1, B, and Lipoprotein(a) levels were measured using
144 immunoturbidimetry (UKB data fields 30630, 30640, 30790). Diastolic and systolic blood
145 pressure was measured at recruitment using automated monitors (UKB data fields 4079,
146 4080). The proportion of missing observations for each measure is presented in **TABLE 1**.
147 Missing observations were not imputed.

148

149 *Pre-processing and quality control of genetic data*

150 To measure *CETP* PTV carrier status, we used the UK Biobank exome
151 sequencing data (UKB data field 23157).²⁵ Population variant call file meta data were
152 annotated using gnomAD v.4.1.0, and Ensembl Variant Effect Predictor v. 111 (VEP).^{21,26}
153 Variants qualified as PTVs if their impact on the MANE transcript (Matched Annotation
154 from NCBI [National Center for Biotechnology Information] and EBI [European
155 Bioinformatics Institute]) were annotated with VEP consequences “frameshift variant”,
156 “splice acceptor variant”, “splice donor variant”, “start lost”, “stop gained”, or “stop lost”,
157 and their allele frequency was <0.001. To prevent batch effect bias, we excluded variants
158 with a genotype depth of coverage (DP) ≤ 10 or were missing in more than 90% of the
159 population. For single nucleotide variants, we further filtered out those with a DP <10,
160 genotype quality (GQ) <20, and a binomial test of the alternate alleles deviation from the

161 heterozygous expectation of 0.5 with a P-value $<1 \times 10^{-3}$. For insertions and deletions, we
162 removed variants with DP <10 and GQ <20 . Details on the 60 different *CETP* PTVs found in
163 the UK Biobank trans-ancestry exome sequencing sample are provided in **SUPPLEMENTAL**
164 **TABLE 1**. In a sensitivity analysis, we assessed the impact of PTV loss-of-function
165 classification using LOFTEE (Loss-Of-Function Transcript Effect Estimator).²⁷ We found
166 no differences in the association between *CETP* PTV carrier status and HDL levels across
167 high-confidence, low-confidence, or not classified PTVs, indicating that LOFTEE
168 classifications were not relevant to *CETP* PTVs (**SUPPLEMENTAL FIGURE 1**).

169

170 *Genetic association studies*

171 The inferential validity of genetic association studies relies on the
172 assumption that the genetic variants under investigation are distributed in a random-like
173 pattern within the study population. This randomness typically occurs because
174 transmission of alleles from parents to offspring, or the emergence of de novo variants, is
175 a random-like natural process that mimics randomization in a clinical trial. Potential
176 confounders, such as population stratification, assortative mating, or relatedness, could
177 however impact the *CETP* PTV–ASCVD association by misbalancing the distribution of
178 non-lipid risk factors between variant carriers and non-carriers.²⁸⁻³⁰ This would be
179 analogous to failure of randomization in a clinical trial. To examine if such sources of bias
180 were present, we tested whether the distribution of non-lipid ASCVD risk factors were
181 similar in *CETP* PTV carriers and non-carriers. *P* values and 95% confidence intervals
182 were computed using t-tests for continuous variables and Fisher’s exact test for
183 categorical variables (see **TABLE 1**).

184 In the analysis of the primary endpoint, the association between *CETP* PTV
185 carrier status and ASCVD was measured using Cox regression, adjusting for age, sex, and
186 the six first genetic principal components (UKB data field 22009). We restricted the
187 sample to European ancestry individuals to limit bias from population stratification. To
188 control for excessive relatedness, only one individual from each group of individuals more
189 closely related than third-degree relatives was selected for further analyses, based on a
190 KING coefficient cut-off of 0.0884.³¹ To reduce genotyping error, we excluded samples
191 that were outliers for heterozygosity (principal components-adjusted heterozygosity

192 >0.1903) or had a missing rate >5%. We also excluded participants with sex chromosome
193 aneuploidies (UKB data field 22019).

194 A trans-ancestry meta-analysis was conducted to determine if the
195 inferences were valid across ancestries. We included a previous study of Nomura et al.,
196 to increase statistical power (80,001 individuals and 44% East Asian, 44% European, 12%
197 South Asian ancestry).³² Compared to the ASCVD composite endpoint used in the UK
198 Biobank analyses, the outcome in the Nomura et al. paper was restricted to coronary
199 heart disease alone. However, both endpoints reflect the same underlying
200 pathophysiological phenotype, atherosclerosis, which justifies their inclusion in the
201 meta-analysis. The odds ratio of ASCVD between *CETP* PTV carriers versus non-carriers
202 was measured in 6908; 409,638; and 6969 UK Biobank participants of African, European,
203 and South Asian ancestry, respectively. To harmonize the unit of effect measurements
204 between the studies, we applied logistic regression with Firth's correction in the UK
205 Biobank subset, while otherwise reusing the analysis strategy described in the previous
206 section.³³ Meta-analysis was conducted using a fixed-effects inverse variance weighted
207 estimator. Study heterogeneity was estimated using Cochran's Q test and calculating the
208 I^2 statistic.

209 Step 2

210 Cumulative LDL cholesterol exposure and atherosclerotic cardiovascular 211 disease risk in genetic studies and clinical trials

212 *Selection of clinical trials and genetic exposures*

213 A list of clinical trials was retrieved from previous systematic reviews of
214 guidelines-recommended lipid-lowering therapies for ASCVD prevention (see
215 **SUPPLEMENTAL TABLE 2** for details).³⁴⁻³⁶ We then added trials involving dialysis and heart
216 failure patients, one post-acute coronary syndrome trial, and the pitavastatin trials.³⁷⁻⁴²
217 The guideline-recommended therapies were statins, ezetimibe, and PCSK9 inhibitors. To
218 obtain precise and unbiased effect estimates, we applied specific selection criteria. First,
219 each trial was required to be designed to measure cardiovascular outcomes as the
220 primary outcome and have recorded more than 100 events. Second, trials that were
221 stopped early due to efficacy were excluded if the information fraction was less than 0.90,

222 as truncated trials tend to overestimate treatment effects, especially when the event rate
223 is low.⁴³ This overestimation is sometimes referred to as the “winner’s curse”. The
224 information fraction was calculated as the ratio of the pre-specified planned events to the
225 actual observed events before termination. Third, to ensure comparability between
226 studies, the effect had to be measured using the hazard ratio (HR) or incidence rate ratio
227 (IRR). The inclusion of studies using IRR for measuring the primary outcome was justified
228 since, in most cases, the IRR closely resembles the HR.⁴⁴ We performed sensitivity
229 analyses to assess the impact of the second selection criteria (see **SUPPLEMENTAL FIGURES**
230 **2-5**). Additionally, we examined whether excluding non-double-blind trials affected the
231 results (**SUPPLEMENTAL FIGURES 6-7**).

232 From each study, we extracted the reported composite outcome most
233 closely resembling the ASCVD composite endpoint described in **STEP 1**. LDL-C reduction
234 from treatment was obtained from the text, or if unavailable, directly from figures using a
235 web-based tool (see **DATA AVAILABILITY**). Other key variables, such as baseline age and
236 baseline LDL-C cholesterol, were extracted from tables, text, or supplemental materials.
237 Regarding CETP inhibitors, we excluded torcetrapib from the meta-analysis due to its off-
238 target toxicity.

239 As a genetic positive control, we assessed the effect of lifetime *LDLR* PTV
240 carrier status (encoding the LDL receptor) on ASCVD risk in the UK Biobank. Carrying an
241 *LDLR* PTV typically meets the genetic diagnostic criteria for heterozygous familial
242 hypercholesterolemia, a condition characterized by increased lifetime LDL-C exposure
243 that profoundly impacts ASCVD risk.⁴⁵ Given the focus on the impact of cumulative LDL-
244 C differences on ASCVD, the *LDLR* PTV carriers served as a relevant genetic comparator
245 to *CETP* PTV carriers. The association between *LDLR* PTV carrier status and ASCVD risk
246 was measured using the same methods as described in the *CETP* PTV analyses in **STEP 1**.
247 Additional details on the UK Biobank *LDLR* PTVs are provided in **SUPPLEMENTAL TABLE 3**.
248 The conditional effect of *CETP* and *LDLR* PTVs on LDL-C were measured using linear
249 regression adjusting for age, sex, and the six first genetic principal components.

250 *LDL cholesterol exposure trajectories and calculation of cumulative LDL cholesterol*
251 *difference*

252 Low-density lipoprotein levels are low at birth, rise with age, and stabilize in
253 late middle age.^{17,46,47} Consequently, lifetime ASCVD risk attributable to LDL-C is a time-
254 varying exposure that needs accounting for to accurately estimate its impact.⁴⁸⁻⁵⁰ For each
255 intervention or genetic exposure, we quantified the reduction in cumulative LDL-C
256 exposure, expressed as “LDL-C Plaque Years Difference”, by integrating over population
257 mean LDL-C life course trajectories (see **FIGURE 1**). First, we adjusted the standard
258 population LDL-C trajectory to match the baseline LDL-C levels of each specific study
259 population. This adjustment was done by scaling the mean LDL-C trajectory using the
260 ratio of the study’s baseline LDL-C level to a general population reference mean LDL-C
261 value (3.55594 mmol/L), accounting for differences in baseline LDL-C levels between
262 population-based studies and clinical trials involving secondary or high-risk prevention
263 populations. The LDL-C trajectories were extracted from references,^{17,46,47} and the exact
264 population trajectories that were used are provided in **SUPPLEMENTAL TABLE 4**.

265 Then, we calculated the area under the LDL-C versus age curve (AUC) from
266 the start of follow-up to the end (defined as the start age plus the median time of follow-
267 up) to represent cumulative LDL-C exposure without intervention. To model the effect of
268 the intervention (or genetic exposure), we adjusted the LDL-C trajectory according to the
269 intervention’s reported effect size. Our approach assumed a time-independent relative
270 lowering of LDL-C levels across the exposure-time trajectory. To reflect this constant
271 relative reduction of LDL-C over time, we applied a scaling factor $k = 1 +$
272 $\frac{LDL-C\ Effect}{LDL-C\ Baseline\ Mean}$ across the intervention or genetic exposure trajectory. We then
273 recalculated the AUC for the adjusted LDL-C trajectory, representing cumulative LDL-C
274 exposure with the intervention (or genetic exposure). The difference between the two
275 AUCs (without and with intervention) therefore reflected the total reduction in cumulative
276 LDL-C exposure due to the intervention (or genetic exposure). These differences were
277 computed for each study and recorded as the “LDL-C Plaque Years Difference”. The
278 measure allowed us to compare how much cumulative LDL-C exposure was lowered in
279 each clinical trial or genetic association study. Reproducible code for these calculations
280 is provided in the **SUPPLEMENTAL NOTE**.

281 *Meta-analysis of genetic and pharmacological cumulative LDL cholesterol lowering and*
282 *atherosclerotic disease risk*

283 To compare CETP inhibition with the guidelines-recommended lipid-
284 lowering therapies and *LDLR* PTVs, we conducted separate analyses for CETP and the
285 other approaches to measure the association between cumulative LDL-C differences and
286 ASCVD risk. We used a fixed-effects inverse variance-weighted estimator to measure the
287 combined effect size across studies. Study heterogeneity was assessed using Cochran's
288 Q test and the I^2 statistic. Leave-one-out sensitivity analyses of effect size and
289 heterogeneity are presented in **SUPPLEMENTAL FIGURE 8**.

290 We performed additional sensitivity analyses because, if atherosclerosis
291 follows a cumulative exposure model, both the magnitude and duration of LDL exposure
292 (LDL-C × follow-up length) should approximately predict the observed risk reductions. We
293 used multiple meta-regression to assess the impact of LDL-C lowering and mean or
294 median follow-up duration on the ASCVD hazard reduction observed in clinical trials. The
295 data were fitted with a linear random-effects mixed model, and restricted maximum
296 likelihood estimated heterogeneity. *P* values were validated using permutation tests.⁵¹ We
297 performed sensitivity analyses by adjusting the interaction term (LDL-C × median time of
298 follow-up) for baseline LDL-C, annual and cumulative event risk, age at enrollment, and
299 year of publication, and used multilevel inference to rank them as predictors
300 (**SUPPLEMENTAL FIGURE 10**).

301 **Ethical review and reporting of statistical tests**

302 This research has been conducted using the UK Biobank Resource under
303 Application Number 148828. The LDL-C trajectory and meta-analyses used publicly
304 available summary data that did not require separate ethical review. The research
305 adhered to the ethical standards set forth in the Declaration of Helsinki. The primary
306 research question in this study was to measure the impact of long-term CETP inhibition
307 on ASCVD risk. The other statistical tests in **STEP 1** were considered secondary endpoints.
308 **STEP 1** and **STEP 2** analyses were separate, and did not require correcting for a family-wise
309 error rate. Consequently, *P* values and 95% confidence intervals reported in this paper
310 are presented without correction for multiple comparisons.

311

312 Results

313 Step 1

314 Protein-truncating variants that inhibit CETP throughout life reduce the risk 315 of atherosclerotic disease

316 Descriptive characteristics on the 409,638 European-ancestry individuals
317 meeting inclusion criteria are presented in **TABLE 1**. The mean age at recruitment into the
318 UK Biobank between 2006–2010 was 56.8 years and 53.9% were female. Genetic
319 exposures begin at conception, and the median time of birth to end of follow-up was 70.2
320 years. Between 1958 and 2023 (median year 2013, interquartile range 2006–2018); 61,091
321 first occurrences of ASCVD were recorded. Details on the composite endpoints are
322 provided in the **METHODS** section and **FIGURE 2**. UK Biobank *CETP* PTV variant types and
323 allele frequencies are listed in **SUPPLEMENTAL TABLE 1**.

324 There were 385 European-ancestry *CETP* PTV carriers available for analysis
325 in the UKB. As anticipated, they presented with elevated HDL cholesterol (+0.42 mmol/L,
326 $P=9\times 10^{-37}$), and lowered LDL cholesterol (-0.18 mmol/L, $P=3\times 10^{-5}$). Apolipoprotein A1 and
327 Apolipoprotein B differed according to a similar pattern (**TABLE 1**). Lipoprotein(a) levels
328 were lower in *CETP* PTV carriers (-6.5 nmol/L, $P=0.021$). Statin treatment was less
329 common in *CETP* PTV carriers (16.3% vs. 12.5%, $P=0.039$). This was expected, as lowered
330 LDL-C from birth should influence a physician's decision to prescribe statins later in life.
331 Non-lipid risk factors and participant characteristics were well-balanced between *CETP*
332 PTV carriers and controls (**TABLE 1**). The only exception was diastolic blood pressure,
333 which was 1.3 mmHg higher in *CETP* PTV carriers ($P=0.043$). It is unclear whether this
334 difference reflects a true effect or was due to multiple comparisons, as previous trials
335 with dalcetrapib, evacetrapib, anacetrapib, and obicetrapib did not report elevations in
336 diastolic blood pressure.^{11-13,52} Overall, these data suggests that the allocation to *CETP*
337 PTVs occurred in a random-like manner, making it unlikely that imbalances in ASCVD risk
338 factors influenced the results.

339 Lifetime *CETP* inhibition from a *CETP* PTV reduced absolute ASCVD risk by
340 4.8 percentage points (**TABLE 1**). The adjusted hazard ratio was 0.65 (95% confidence
341 interval, 0.48–0.90, P value = 0.008). This risk reduction corresponded to an average gain

342 of 1.1 years in ASCVD event-free survival before the age of 80 (**FIGURE 2A**). Although the
343 secondary endpoints had overlapping CIs and were not statistically distinguishable, the
344 association between *CETP* PTVs and the composite ASCVD endpoint seemed to be
345 primarily driven by coronary heart disease and ischemic stroke events (**FIGURE 2B**).
346 Notably, *CETP* PTV carrier status did not significantly affect all-cause mortality but
347 reduced the risk of a composite endpoint of ASCVD or all-cause death (**FIGURE 2B**).

348 The trans-ancestry meta-analysis included 506,516 individuals: 6908 of
349 African; 36,856 of East Asian; 446,157 of European; and 16,595 of South Asian ancestry.
350 Among them, 679 were *CETP* PTV carriers. There were 95,568 ASCVD cases and 410,948
351 controls. Between-study heterogeneity was low ($Q = 3.39$, P value = 0.34, $I^2 = 11.5\%$).
352 Lifetime *CETP* inhibition was associated with a reduced ASCVD risk, with an odds ratio of
353 0.70 (95% confidence interval, 0.57–0.85, meta-analysis P value = 4.7×10^{-4}) (**FIGURE 2C**).
354 Taken together, these results indicate that lifetime *CETP* inhibition significantly reduces
355 ASCVD risk, with no evidence of this effect being dependent on genetic ancestry.

356 Step 2

357 *CETP* inhibition reduces atherosclerotic disease risk by lowering LDL

358 Data on ASCVD risk reduction, baseline LDL-C, LDL-C lowering, age, and
359 median or mean time of follow-up were extracted from 47 clinical trials of *CETP* inhibitors,
360 statins, ezetimibe, and PCSK9 inhibitors. Four trials were excluded because they were not
361 designed to assess treatment effects on clinical cardiovascular endpoints. Eight trials
362 terminated early for efficacy were excluded to prevent inflated effect estimates due to the
363 “winner’s curse”. One trial was excluded for not reporting outcomes as hazard ratios or
364 incidence rate ratios, making it incomparable to the other trials.

365 The remaining 34 cardiovascular outcomes trials covered a population of
366 328,036 individuals with 53,161 ASCVD events across both primary and secondary
367 prevention settings. Three trials studied *CETP* inhibitors ($n_{\text{total}}=58,412$; $n_{\text{events}}=7126$), 23
368 trials evaluated statins ($n_{\text{total}}=160,910$; $n_{\text{events}}=31,854$), three examined ezetimibe
369 monotherapy ($n_{\text{total}}=23,645$; $n_{\text{events}}=6271$), two were of ezetimibe/statin combination
370 therapy ($n_{\text{total}}=11,143$; $n_{\text{events}}=1480$), and three investigated PCSK9 inhibitors ($n_{\text{total}}=73,926$;
371 $n_{\text{events}}=6430$). Age at enrollment ranged from 49.8 to 75.4 years, with follow-up durations

372 between 0.3 and 6.7 years. Baseline LDL-C ranged from 1.58 to 4.97 mmol/L, with
373 reductions between 0.03 and 1.80 mmol/L. Twenty-nine trials were double-blind, and five
374 were not. Further details, including study settings and extracted endpoints, are provided
375 in **SUPPLEMENTAL TABLE 2**.

376 To determine whether the clinical trial data aligned with the cumulative LDL
377 exposure hypothesis of atherosclerosis, we used multiple meta-regression to assess the
378 impact of LDL-C lowering magnitude and duration on ASCVD risk. We identified a
379 significant interaction between LDL-C reduction and time of follow-up ($P = 0.007$) (see
380 **FIGURE 3**). Sensitivity analyses confirmed the robustness of this association
381 (**SUPPLEMENTAL FIGURES 9-10**). These data support the hypothesis that LDL-C's effect on
382 ASCVD risk follows a cumulative exposure model and provide a theoretical basis for
383 modeling genetic effects alongside clinical trial data, as described next.

384 We compared genetic and pharmacological CETP inhibition with guideline-
385 recommended lipid-lowering therapies and *LDLR* PTVs to evaluate their effects on ASCVD
386 relative to cumulative LDL-C lowering. We found that the predicted effect of CETP
387 inhibition was similar to the combined estimate from statins, PCSK9 inhibitors, ezetimibe,
388 and *LDLR* PTVs (hazard ratio: 0.76 vs. 0.69 per 10 mmol/L × years) (**FIGURE 4**). Since CETP
389 inhibition and the other pathways produced comparable effects per unit of cumulative
390 LDL-C reduction, these results suggest that CETP inhibition reduces ASCVD risk primarily
391 by lowering LDL-C.

392 Nine out of eleven lipid-lowering trials with cumulative LDL-C reductions
393 below 2.5 mmol/L × years did not achieve a statistically significant reduction in ASCVD
394 events, as indicated by 95% confidence intervals overlapping the null in **FIGURE 4**. Only
395 two trials (PROVE-IT and IMPROVE-IT) with reductions below this threshold had
396 confidence intervals that did not overlap the null. These data suggest that the LDL-C
397 reductions in the evacetrapib and dalcetrapib trials were too small to yield a statistically
398 significant decrease in ASCVD events. Moreover, this issue appears not to be unique to
399 CETP inhibitors but applies to LDL-C lowering therapies in general. To demonstrate
400 stronger effects on clinical endpoints, future trials could target greater cumulative LDL-C
401 reductions.

402

403 Discussion

404 The failure of the early CETP inhibitors in cardiovascular outcomes trials
405 surprised many and raised doubts about the efficacy of CETP inhibition in ASCVD
406 prevention. In contrast, our study shows that individuals carrying a single defective *CETP*
407 allele since birth, leading to lifelong partial CETP inhibition, have a significantly reduced
408 risk of developing ASCVD. This finding aligns with previous genetic studies on both
409 common and rare loss-of-function *CETP* variants across diverse populations,^{32,53-57}
410 reinforcing the potential of CETP inhibition as a promising strategy for ASCVD prevention.

411 To reconcile the discrepancy between the promising genetic data and mixed
412 clinical trial results, we applied the hypothesis that cumulative lifetime LDL-C exposure
413 plays a critical role in ASCVD development. This concept aligns with the pathophysiology
414 of atherosclerosis, which suggests that both the magnitude and duration of LDL-C
415 exposure drive disease progression through plaque formation.¹⁷ A key strength of our
416 study was the estimation of cumulative LDL-C differences over time, providing a more
417 biologically accurate assessment of LDL-lowering effects on ASCVD risk.

418 By analyzing data from individuals with *CETP* and *LDLR* PTVs, along with
419 cardiovascular outcomes trials of lipid-lowering therapies, we identified a strong linear
420 relationship between reductions in cumulative LDL-C exposure and decreases in ASCVD
421 risk. Notably, clinical trials that did not achieve substantial and sustained LDL-C
422 reductions over time, regardless of the therapeutic mechanism, including CETP
423 inhibitors, statins, or PCSK9 inhibitors, were significantly less likely to show clinical
424 benefit. These findings suggest that the lack of efficacy seen in the evacetrapib and
425 dalcetrapib trials was not specific to the particular class of drugs but was instead due to
426 insufficient LDL lowering and the short duration of the trials.

427 Our analysis demonstrated that both LDL-C reduction magnitude and
428 treatment duration were independent predictors of ASCVD risk reduction. Furthermore,
429 we identified a significant interaction between these factors, providing strong support for
430 the cumulative LDL hypothesis. A key strength of the meta-analysis was the use of strict
431 exclusion criteria to eliminate trials that were likely to report inflated effect estimates.⁴³
432 Our findings are consistent with another meta-analysis of 21 trials that focused on

433 minimizing bias from small-study effects while also excluding trials with less than 3 years
434 of follow-up.⁵⁸

435 These results indicate that instrumental variable analysis using human
436 genetics can yield accurate treatment effect estimates when time-varying exposures are
437 assessed and accounted for. Previous studies have suggested that genetic analyses may
438 overestimate the impact of LDL-C lowering on ASCVD risk,⁵⁰ potentially due to imprecise
439 measurement of the exposure variable. Specifically, equating exposure to the effect of
440 genetic variants on LDL-C at a single time point assumes that ASCVD risk reduction is
441 driven by a constant, time-independent, and absolute LDL-C lowering. Given the
442 progressive nature of atherosclerosis and the variation in LDL-C levels throughout life,
443 this assumption may not be valid.

444 This highlights that an important difference between genetic and
445 pharmacological effects lies in the timing and duration of exposure and the length of
446 follow-up. Genetic exposures begin at conception and persist throughout life, whereas
447 clinical trials administer treatments to adults and generally follow participants for only a
448 few years. Since atherosclerosis can begin early in life and is driven by cumulative LDL-C
449 retention,^{16,17} accounting for lifelong time-varying exposure is essential for accurate
450 estimation of treatment effects.

451 In this study, we addressed this by modeling LDL-C reductions using
452 population-averaged life-course trajectories. While this method improves accuracy over
453 assuming time-independent absolute LDL-C reductions, it has limitations. Specifically,
454 we did not account for individual variations in LDL-C trajectories across different
455 populations (besides correcting for baseline levels), nor did we consider complex, non-
456 linear interactions with treatments or risk factors such as diabetes, hypertension,
457 inflammation, severely elevated Lipoprotein(a) levels, or lifestyle. Future studies should
458 aim to use within-sample LDL-C trajectories and consider individual-level models to
459 enhance the precision of cumulative LDL-C exposure measurements.

460 Another limitation of this study was that we did not investigate genetic CETP
461 inhibition in its homozygous state. Heterozygous *CETP* PTV carriers showed LDL-C
462 reductions of -0.19 mmol/L, whereas potent CETP inhibitors reduced LDL-C by up to five
463 times more (-0.98 mmol/L).¹⁵ From these genetic data, it is unclear whether increased
464 genetic CETP inhibition leads to proportionally greater benefits. However, anacetrapib

465 100 mg daily achieved 80% CETP inhibition and demonstrated similar clinical benefits to
466 *CETP* PTV carriers (per unit of cumulative LDL-C lowering),^{13,59} suggesting that the genetic
467 effects may be generalizable (**FIGURE 3**).

468 These findings have important clinical implications that require confirmation
469 in clinical trials. They suggest that maximizing the benefits of LDL-C lowering depends on
470 achieving substantial and sustained reductions over extended periods. They also
471 highlight the need for further research in early intervention and long-term adherence to
472 both lifestyle and pharmacological lipid-lowering interventions. Future clinical trials
473 should consider the impact of LDL-C over time in their design to better assess the efficacy
474 of lipid-lowering therapies for ASCVD prevention.

475 In conclusion, we predict that future CETP inhibitor trials achieving
476 substantial and sustained LDL-C lowering will demonstrate efficacy in preventing ASCVD.
477 Our findings emphasize the importance of sustained LDL-C reduction over time and
478 support the continued investigation of CETP inhibition as a therapeutic strategy for
479 ASCVD prevention.

480

481 Acknowledgements

482 This research has been conducted using the UK Biobank Resource under Application
483 Number 148828. We thank the UK Biobank participants for their important contributions
484 to medical research. The graphical abstract was created in BioRender (Landfors, F. (2024)
485 <https://BioRender.com/j51i966>).

486 Funding

487 This work was supported by grants from the Northern Sweden Heart Fund, and received
488 financial support from New Amsterdam Pharma Company N.V.

489 Conflict of interest

490 Fredrik Landfors is a part-time clinical scientist at Lipigon Pharmaceuticals AB. John J.P.
491 Kastelein is the chief scientific officer of NewAmsterdam Pharma N.V. Elin Chorell has no
492 conflicts of interest to declare.

493 Data availability

494 UK Biobank data is available to authorized researchers. Researchers interested in
495 accessing the data must complete an application process with UK Biobank. The
496 identifiers for the UK Biobank datasets used in the analyses are described in the **METHODS**
497 section. All publicly available scientific data that were used for the analyses of this paper
498 are provided in the manuscript or supplemental material. Plots were digitized using the
499 University of Tennessee-Knoxville WebPlotDigitizer v.3.4
500 (<https://web.eecs.utk.edu/~dcostine/personal/PowerDeviceLib/DigiTest/index.html>).

501

502 Legends

503 Table 1

504 **Characteristics of the European-ancestry United Kingdom Biobank cohort.**

505 All measurements, except for the atherosclerotic cardiovascular disease-related primary
506 and secondary endpoints, were taken at the time of entry into the United Kingdom
507 Biobank. To protect privacy, cell counts of five or fewer are reported as ‘≤5’.

508 Figure 1

509 **Comparison of LDL cholesterol trajectories in genetic studies and clinical trials.**

510 This schematic compares LDL cholesterol trajectories from genetic effects versus clinical
511 interventions. The left panel shows a modest, lifelong reduction in LDL cholesterol
512 beginning at conception due to *CETP* protein-truncating variants (PTVs). In contrast, the
513 right panel illustrates a more substantial reduction starting in adulthood, as seen in the
514 Scandinavian Simvastatin Survival Study (4S). Despite differences in onset and
515 magnitude, both approaches lead to similar reductions of cumulative LDL cholesterol
516 exposure over time. The cumulative LDL cholesterol lowering for each scenario
517 corresponds to the values shown on the x-axis of **FIGURE 4**.

518 Figure 2

519 **Association of *CETP* protein-truncating variants with cardiovascular endpoints.**

520 **(A)** Kaplan-Meier survival curves comparing cumulative survival (left panel) and event-
521 free survival (right panel) between carriers of *CETP* protein-truncating variants (PTVs) (n =
522 385) and non-carriers (n = 409,253) in the European-ancestry subset of the UK Biobank.
523 Shaded areas around each curve represent the 95% confidence intervals. Curves were
524 truncated when the at-risk population fell below 10 participants.

525 **(B)** Forest plot showing the association between *CETP* PTVs and primary and secondary
526 cardiovascular endpoints.

527 **(C)** Forest plot showing the trans-ancestry meta-analysis combining UK Biobank results
528 with data from previous studies of *CETP* PTVs.³² Ancestries are denoted as: ‘Eur’ for
529 European, ‘Afr.’ for African, and ‘S. As’ for South Asian. ‘ASCVD’ denotes atherosclerotic
530 cardiovascular disease, and “CHD” denotes coronary heart disease.

531 **Figure 3**

532 **Atherosclerotic risk reduction from the magnitude and duration of LDL cholesterol**
533 **lowering in clinical trials.**

534 Meta-regression scatterplot illustrating the association between atherosclerotic
535 cardiovascular disease (ASCVD) risk reduction and the interaction between LDL-C
536 lowering and median time of follow-up in clinical trials. The clinical trials investigated
537 statins, ezetimibe, PCSK9 and CETP inhibitors. Each point represents a clinical trial, with
538 size of the circles reflecting the weight of the trial in the meta-regression analysis. The
539 solid line shows the association between the observed treatment effects on
540 atherosclerotic vascular disease risk and the cumulative LDL differences (LDL × time)
541 observed during follow-up, and the dashed lines represents the 95% confidence interval
542 (CI).

543 ‘QE’ denotes test for residual heterogeneity

544 **Figure 4**

545 **Relationship between cumulative LDL cholesterol reduction and atherosclerotic**
546 **cardiovascular disease risk reduction across multiple mechanisms.**

547 The regression scatterplot shows the relationship between cumulative LDL cholesterol
548 (LDL-C) reduction (measured in LDL-C plaque years) and atherosclerotic cardiovascular
549 disease (ASCVD) risk reduction achieved through CETP inhibition, statins, ezetimibe,
550 PCSK9 inhibitors, and the LDL receptor (LDLR). Each point represents a clinical trial or
551 genetics study, with circle sizes reflecting study weight in the meta-analysis. Risk
552 reductions were observed either between treatment arms or between carriers of protein-
553 truncating variants (PTVs) and controls. Solid lines indicate meta-analysis treatment
554 effect estimates, with shaded areas showing 95% confidence intervals (CIs). Individual
555 study effect estimates are marked by data points with attached vertical lines representing
556 95% CIs.

557 ‘HR’ denotes hazard ratio, and ‘IRR’ denotes incidence rate ratio. Drug targets are
558 indicated as: ‘HMGCR’ for HMG-CoA Reductase (statins), ‘NPC1L1’ for Niemann-Pick C1-
559 Like 1 (ezetimibe), and ‘PCSK9’ for PCSK9 inhibitors. ‘LDLR PTVs’ refer to protein-
560 truncating variants in the LDL receptor.

561 † To simplify visualization, carriers of *LDLR* PTVs (familial hypercholesterolemia-
562 associated variants) were used as the reference group. Compared to controls (n =
563 409,539), *LDLR* PTV carriers (n = 99) had a higher ASCVD risk, with a hazard ratio of 4.44
564 (95% CI: 3.27–6.04).

565 Appendices

566 *Supplemental note*

567 **R script for estimating LDL-C Plaque Years Difference.**

568 This script provides reproducible code for estimating cumulative LDL cholesterol (LDL-C)
569 lowering from clinical trials or genetic exposures, as described in the paper.

570 Supplemental figures

571 *Supplemental figure 1*

572 **Association between HDL cholesterol and *CETP* Loss-Of-Function Transcript Effect 573 Estimator (LOFTEE) protein-truncating variant (PTV) classifications.**

574 Tukey Box plot showing there were no meaningful differences between LOFTEE PTV
575 classifications with regards to plasma HDL cholesterol (HDL-C) levels. The analysis was
576 conducted in 357,794 European ancestry United Kingdom Biobank participants. The
577 association between *CETP* PTV classifications were tested using analysis of variance.
578 Welch's *F* test indicated unequal variances ($P = 3.0 \times 10^{-25}$). *Post hoc* tests indicated there
579 were no significant differences between predicted low-confidence and high-confidence
580 *CETP* PTVs ($P = 0.55$). However, HDL-C levels were elevated in both high- and low-
581 confidence *CETP* PTV carriers compared to non-carriers ($P = 2.3 \times 10^{-12}$, and $P = 2.4 \times 10^{-6}$,
582 respectively). There were only two individuals carrying non-classified predicted *CETP*
583 PTVs, and their HDL-C levels were nominally higher than non-carriers, but nominally
584 lower than low- or high-confidence *CETP* PTV carriers ($\hat{\mu}_{\text{mean}} = 1.55$ mmol/L). Since the
585 HDL-C levels were similar across the LOFTEE categories, we conclude that LOFTEE
586 classifications were irrelevant as they did not predict the *CETP* PTVs impact on *CETP*
587 activity as measured through plasma HDL-C concentrations.

588 *Supplemental figure 2*

589 **Sensitivity analysis of atherosclerotic risk reduction from cumulative LDL 590 cholesterol lowering, including trials terminated early due to efficacy.**

591 The meta-analysis followed the same procedure as in **FIGURE 3** but retained trials that
592 were stopped early for efficacy.

593 *Supplemental figure 3*

594 **Leave-one-out sensitivity analysis of the pooled effect size and heterogeneity for**
595 **ASCVD risk reduction from cumulative LDL-C lowering, based on SUPPLEMENTAL**
596 **FIGURE 2.**

597 Each study was sequentially excluded to measure its influence on the overall association.

598 *Supplemental figure 4*

599 **Sensitivity analysis of atherosclerotic risk reduction from cumulative LDL**
600 **cholesterol lowering, including and penalizing trials terminated early due to efficacy.**

601 The meta-analysis followed the same procedure as in **FIGURE 4** but included trials
602 stopped early for efficacy, penalizing their effect estimates (natural logarithm of the
603 hazard ratio) by multiplication with their information criterion (see the **METHODS** section
604 for definition).

605 *Supplemental figure 5*

606 **Leave-one-out sensitivity analysis of the pooled effect size and heterogeneity for**
607 **atherosclerotic cardiovascular disease risk reduction from cumulative LDL**
608 **cholesterol lowering, based on SUPPLEMENTAL FIGURE 4.**

609 Each study was sequentially excluded to assess its influence on the overall association.

610 *Supplemental figure 6*

611 **Sensitivity analysis of atherosclerotic risk reduction from cumulative LDL**
612 **cholesterol lowering, excluding non–double-blind clinical trials.**

613 The meta-analysis was conducted using the same methods as in **FIGURE 4** but excluded
614 non–double-blind trials.

615 *Supplemental figure 7*

616 **Leave-one-out sensitivity analysis of the pooled effect size and heterogeneity for**
617 **atherosclerotic cardiovascular disease risk reduction from cumulative LDL**
618 **cholesterol lowering, based on SUPPLEMENTAL FIGURE 6.**

619 Each study was sequentially excluded to assess its influence on the overall association
620 between LDL cholesterol reduction and ASCVD risk.

621 *Supplemental figure 8*

622 **Leave-one-out sensitivity analysis of the pooled effect size and heterogeneity for**
623 **atherosclerotic cardiovascular disease risk reduction from cumulative LDL**
624 **cholesterol lowering, based on FIGURE 4.**

625 Each study was sequentially excluded to assess its influence on the overall association
626 between LDL cholesterol reduction and ASCVD risk.

627 *Supplemental figure 9*

628 **Supplemental Figure 9. Meta-regression analyses for atherosclerotic disease risk**
629 **reduction based on LDL-C reduction times the median time of follow-up.**

630 **(A)** The left scatterplot regression line shows the association between LDL-C (low-density
631 lipoprotein cholesterol) reduction and atherosclerotic cardiovascular disease (ASCVD)
632 risk reduction conditioning on median time of follow-up. The right scatterplot regression
633 line shows ASCVD risk as a function of adjusted median time of follow-up by LDL-C
634 reduction.

635 **(B)** The scatterplots show meta-regressions with an interaction term between LDL-C
636 reduction and median time of follow-up. The top plot regression slope shows the adjusted
637 ASCVD risk as a function of the interaction between LDL-C reduction and median time of
638 follow-up (mmol/L × years). The two bottom plots show the separate effects of LDL-C
639 reduction (left) and median time of follow-up (right) on ASCVD risk, taking the interaction
640 term into account.

641 Dashed lines indicate confidence intervals. Larger circle sizes correspond to studies with
642 greater weight in the analysis. ‘HR’ denotes hazard ratio, and ‘IRR’ denotes incidence rate
643 ratio.

644 *Supplemental figure 10*

645 **Supplemental Figure 10. Meta-regression sensitivity and multi-model inference**
646 **analyses**

647 **(A)** The table shows adjusted models of the interaction between LDL cholesterol (LDL-C)
648 reduction and the median time of follow-ups across atherosclerotic cardiovascular
649 disease (ASCVD) risk reduction in clinical trials. Model 1 includes the interaction between
650 LDL-C reduction and median time of follow-up, while models 2–6 adds a single
651 adjustment for either baseline LDL-C, annualized risk, cumulative risk, mean age, and

652 year of publication. The interaction regression coefficients (β), standard errors (SE), p-
653 values, and permutation-based p-values are shown in separate columns.

654 **(B)** This bar plot shows the ranking of the importance of predictor variables in explaining
655 ASCVD risk reduction as observed in the clinical trials.

656 Supplemental tables

657 *Supplemental table 1*

658 **UK Biobank *CETP* protein-truncating variants.**

659 This table lists the protein-truncating variants (PTVs) in *CETP* (encoding the cholesteryl
660 ester transfer protein) that were analyzed in the United Kingdom Biobank (see **STEP 1**). It
661 includes variant identifiers, genomic positions, allele frequencies, and Ensembl Variant
662 Effect Predictor predicted consequences.

663 *Supplemental table 2*

664 **Cumulative LDL cholesterol exposure versus atherosclerotic cardiovascular disease 665 risk.**

666 This table includes summary data from clinical trials and genetic association studies
667 relevant to the analysis of cumulative LDL cholesterol exposure in relation to
668 atherosclerotic cardiovascular disease risk, which are presented in **FIGURE 3** and
669 **SUPPLEMENTAL FIGURES 2-12.**

670 *Supplemental table 3*

671 **UK Biobank *LDLR* protein-truncating variants.**

672 This table lists the protein-truncating variants (PTVs) in *LDLR* (encoding the low-density
673 lipoprotein receptor) that were analyzed in the United Kingdom Biobank (see **STEP 1**). It
674 includes variant identifiers, genomic positions, allele frequencies, and Ensembl Variant
675 Effect Predictor predicted consequences.

676

677 *Supplemental table 4*

678 **Low-density lipoprotein cholesterol life-course trajectories.**

679 This table presents averaged life-course trajectories of low-density lipoprotein (LDL)
680 cholesterol levels derived from population-based cohorts.^{17,46,47} These data were used in
681 the analyses presented in **FIGURE 1**, **FIGURE 4**, and **SUPPLEMENTAL FIGURES 2-8.**

682

683 References

- 684 1. Morton RE, Zilversmit DB. Purification and characterization of lipid transfer
685 protein(s) from human lipoprotein-deficient plasma. *J Lipid Res.* Sep 1982;23(7):1058-
686 67.
- 687 2. Drayna D, Jarnagin AS, McLean J, et al. Cloning and sequencing of human
688 cholesteryl ester transfer protein cDNA. *Nature.* 1987 Jun 18-24 1987;327(6123):632-4.
689 doi:10.1038/327632a0
- 690 3. Tall AR, Rader DJ. Trials and Tribulations of CETP Inhibitors. *Circ Res.* Jan 05
691 2018;122(1):106-112. doi:10.1161/CIRCRESAHA.117.311978
- 692 4. Millar JS, Reyes-Soffer G, Jumes P, et al. Anacetrapib lowers LDL by
693 increasing ApoB clearance in mildly hypercholesterolemic subjects. *J Clin Invest.* Jun
694 2015;125(6):2510-22. doi:10.1172/JCI80025
- 695 5. Ikewaki K, Nishiwaki M, Sakamoto T, et al. Increased catabolic rate of low
696 density lipoproteins in humans with cholesteryl ester transfer protein deficiency. *J Clin
697 Invest.* Sep 1995;96(3):1573-81. doi:10.1172/JCI118196
- 698 6. Nicholls SJ, Ruotolo G, Brewer HB, et al. Cholesterol Efflux Capacity and
699 Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With
700 Evacetrapib. *J Am Coll Cardiol.* Nov 17 2015;66(20):2201-2210.
701 doi:10.1016/j.jacc.2015.09.013
- 702 7. Yvan-Charvet L, Kling J, Pagler T, et al. Cholesterol efflux potential and
703 antiinflammatory properties of high-density lipoprotein after treatment with niacin or
704 anacetrapib. *Arterioscler Thromb Vasc Biol.* Jul 2010;30(7):1430-8.
705 doi:10.1161/ATVBAHA.110.207142
- 706 8. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at
707 high risk for coronary events. *N Engl J Med.* Nov 22 2007;357(21):2109-22.
708 doi:10.1056/NEJMoa0706628
- 709 9. Johns DG, Duffy J, Fisher T, Hubbard BK, Forrest MJ. On- and off-target
710 pharmacology of torcetrapib: current understanding and implications for the structure
711 activity relationships (SAR), discovery and development of cholesteryl ester-transfer
712 protein (CETP) inhibitors. *Drugs.* Mar 05 2012;72(4):491-507. doi:10.2165/11599310-
713 000000000-00000
- 714 10. Kastelein JJP, Hsieh A, Dicklin MR, Ditmarsch M, Davidson MH. Obicetrapib:
715 Reversing the Tide of CETP Inhibitor Disappointments. *Curr Atheroscler Rep.* Feb
716 2024;26(2):35-44. doi:10.1007/s11883-023-01184-1
- 717 11. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with
718 a recent acute coronary syndrome. *N Engl J Med.* Nov 29 2012;367(22):2089-99.
719 doi:10.1056/NEJMoa1206797
- 720 12. Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and Cardiovascular
721 Outcomes in High-Risk Vascular Disease. *N Engl J Med.* May 18 2017;376(20):1933-
722 1942. doi:10.1056/NEJMoa1609581
- 723 13. Bowman L, Hopewell JC, Chen F, et al. Effects of Anacetrapib in Patients
724 with Atherosclerotic Vascular Disease. *N Engl J Med.* Sep 28 2017;377(13):1217-1227.
725 doi:10.1056/NEJMoa1706444
- 726 14. Johns DG, Wang SP, Rosa R, et al. Impact of drug distribution into adipose
727 on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as
728 a test case. *Pharmacol Res Perspect.* Dec 2019;7(6):e00543. doi:10.1002/prp2.543

- 729 15. Nicholls SJ, Ditmarsch M, Kastelein JJ, et al. Lipid lowering effects of the
730 CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized
731 phase 2 trial. *Nat Med*. Aug 2022;28(8):1672-1678. doi:10.1038/s41591-022-01936-7
732 16. HOLMAN RL, MCGILL HC, STRONG JP, GEER JC. The natural history of
733 atherosclerosis: the early aortic lesions as seen in New Orleans in the middle of the
734 the 20th century. *Am J Pathol*. 1958;34(2):209-35.
- 735 17. Ference BA, Braunwald E, Catapano AL. The LDL cumulative exposure
736 hypothesis: evidence and practical applications. *Nat Rev Cardiol*. Oct 2024;21(10):701-
737 716. doi:10.1038/s41569-024-01039-5
- 738 18. Rivas MA, Pirinen M, Conrad DF, et al. Human genomics. Effect of predicted
739 protein-truncating genetic variants on the human transcriptome. *Science*. May 08
740 2015;348(6235):666-9. doi:10.1126/science.1261877
- 741 19. DeBoever C, Tanigawa Y, Lindholm ME, et al. Medical relevance of protein-
742 truncating variants across 337,205 individuals in the UK Biobank study. *Nat Commun*.
743 Apr 24 2018;9(1):1612. doi:10.1038/s41467-018-03910-9
- 744 20. Dhindsa RS, Burren OS, Sun BB, et al. Rare variant associations with
745 plasma protein levels in the UK Biobank. *Nature*. Oct 2023;622(7982):339-347.
746 doi:10.1038/s41586-023-06547-x
- 747 21. Minikel EV, Karczewski KJ, Martin HC, et al. Evaluating drug targets through
748 human loss-of-function genetic variation. *Nature*. May 2020;581(7809):459-464.
749 doi:10.1038/s41586-020-2267-z
- 750 22. Trajanoska K, Bhérer C, Taliun D, Zhou S, Richards JB, Mooser V. From target
751 discovery to clinical drug development with human genetics. *Nature*. Aug
752 2023;620(7975):737-745. doi:10.1038/s41586-023-06388-8
- 753 23. Minikel EV, Painter JL, Dong CC, Nelson MR. Refining the impact of genetic
754 evidence on clinical success. *Nature*. May 2024;629(8012):624-629.
755 doi:10.1038/s41586-024-07316-0
- 756 24. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource
757 for identifying the causes of a wide range of complex diseases of middle and old age.
758 *PLoS Med*. Mar 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779
- 759 25. Szustakowski JD, Balasubramanian S, Kvikstad E, et al. Advancing human
760 genetics research and drug discovery through exome sequencing of the UK Biobank. *Nat*
761 *Genet*. Jul 2021;53(7):942-948. doi:10.1038/s41588-021-00885-0
- 762 26. McLaren W, Gil L, Hunt SE, et al. The Ensembl Variant Effect Predictor.
763 *Genome Biol*. Jun 06 2016;17(1):122. doi:10.1186/s13059-016-0974-4
- 764 27. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint
765 spectrum quantified from variation in 141,456 humans. *Nature*. May
766 2020;581(7809):434-443. doi:10.1038/s41586-020-2308-7
- 767 28. Yamamoto K, Sonehara K, Namba S, et al. Genetic footprints of assortative
768 mating in the Japanese population. *Nat Hum Behav*. Jan 2023;7(1):65-73.
769 doi:10.1038/s41562-022-01438-z
- 770 29. Abdellaoui A, Hugh-Jones D, Yengo L, et al. Genetic correlates of social
771 stratification in Great Britain. *Nat Hum Behav*. Dec 2019;3(12):1332-1342.
772 doi:10.1038/s41562-019-0757-5
- 773 30. Howe LJ, Nivard MG, Morris TT, et al. Within-sibship genome-wide
774 association analyses decrease bias in estimates of direct genetic effects. *Nat Genet*.
775 May 2022;54(5):581-592. doi:10.1038/s41588-022-01062-7

- 776 31. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM. Robust
777 relationship inference in genome-wide association studies. *Bioinformatics*. Nov 15
778 2010;26(22):2867-73. doi:10.1093/bioinformatics/btq559
- 779 32. Nomura A, Won HH, Khera AV, et al. Protein-Truncating Variants at the
780 Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease. *Circ Res*.
781 Jun 23 2017;121(1):81-88. doi:10.1161/CIRCRESAHA.117.311145
- 782 33. FIRTH D. BIAS REDUCTION OF MAXIMUM-LIKELIHOOD-ESTIMATES. Article.
783 *Biometrika*. MAR 1993 1993;80(1):27-38. doi:10.1093/biomet/80.1.27
- 784 34. Burger PM, Dorresteyn JAN, Koudstaal S, et al. Course of the effects of LDL-
785 cholesterol reduction on cardiovascular risk over time: A meta-analysis of 60
786 randomized controlled trials. *Atherosclerosis*. Sep 2024;396:118540.
787 doi:10.1016/j.atherosclerosis.2024.118540
- 788 35. Khan SU, Khan MU, Valavoor S, et al. Association of lowering apolipoprotein
789 B with cardiovascular outcomes across various lipid-lowering therapies: Systematic
790 review and meta-analysis of trials. *Eur J Prev Cardiol*. Aug 2020;27(12):1255-1268.
791 doi:10.1177/2047487319871733
- 792 36. Navarese EP, Robinson JG, Kowalewski M, et al. Association Between
793 Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A
794 Systematic Review and Meta-analysis. *JAMA*. Apr 17 2018;319(15):1566-1579.
795 doi:10.1001/jama.2018.2525
- 796 37. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2
797 diabetes mellitus undergoing hemodialysis. *N Engl J Med*. Jul 21 2005;353(3):238-48.
798 doi:10.1056/NEJMoa043545
- 799 38. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and
800 cardiovascular events in patients undergoing hemodialysis. *N Engl J Med*. Apr 02
801 2009;360(14):1395-407. doi:10.1056/NEJMoa0810177
- 802 39. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with
803 systolic heart failure. *N Engl J Med*. Nov 29 2007;357(22):2248-61.
804 doi:10.1056/NEJMoa0706201
- 805 40. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on
806 early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a
807 randomized controlled trial. *JAMA*. Apr 04 2001;285(13):1711-8.
808 doi:10.1001/jama.285.13.1711
- 809 41. Taguchi I, Iimuro S, Iwata H, et al. High-Dose Versus Low-Dose Pitavastatin
810 in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized
811 Superiority Trial. *Circulation*. May 08 2018;137(19):1997-2009.
812 doi:10.1161/CIRCULATIONAHA.117.032615
- 813 42. Grinspoon SK, Fitch KV, Zanni MV, et al. Pitavastatin to Prevent
814 Cardiovascular Disease in HIV Infection. *N Engl J Med*. Aug 24 2023;389(8):687-699.
815 doi:10.1056/NEJMoa2304146
- 816 43. Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for
817 benefit and estimation of treatment effects: systematic review and meta-regression
818 analysis. *JAMA*. Mar 24 2010;303(12):1180-7. doi:10.1001/jama.2010.310
- 819 44. Hernán MA. The hazards of hazard ratios. *Epidemiology*. Jan 2010;21(1):13-
820 5. doi:10.1097/EDE.0b013e3181c1ea43

- 821 45. McGowan MP, Hosseini Dehkordi SH, Moriarty PM, Duell PB. Diagnosis and
822 Treatment of Heterozygous Familial Hypercholesterolemia. *J Am Heart Assoc*. Dec 17
823 2019;8(24):e013225. doi:10.1161/JAHA.119.013225
- 824 46. Gozlan O, Gross D, Gruener N. Lipoprotein levels in newborns and
825 adolescents. *Clin Biochem*. Aug 1994;27(4):305-6. doi:10.1016/0009-9120(94)90033-7
- 826 47. Skinner AC, Steiner MJ, Chung AE, Perrin EM. Cholesterol curves to identify
827 population norms by age and sex in healthy weight children. *Clin Pediatr (Phila)*. Mar
828 2012;51(3):233-7. doi:10.1177/0009922811430344
- 829 48. Labrecque JA, Swanson SA. Interpretation and Potential Biases of
830 Mendelian Randomization Estimates With Time-Varying Exposures. *Am J Epidemiol*. Jan
831 01 2019;188(1):231-238. doi:10.1093/aje/kwy204
- 832 49. Morris TT, Heron J, Sanderson ECM, Davey Smith G, Didelez V, Tilling K.
833 Interpretation of Mendelian randomization using a single measure of an exposure that
834 varies over time. *Int J Epidemiol*. Dec 13 2022;51(6):1899-1909. doi:10.1093/ije/dyac136
- 835 50. Burgess S, Butterworth A, Malarstig A, Thompson SG. Use of Mendelian
836 randomisation to assess potential benefit of clinical intervention. *BMJ*. Nov 06
837 2012;345:e7325. doi:10.1136/bmj.e7325
- 838 51. Higgins JP, Thompson SG. Controlling the risk of spurious findings from
839 meta-regression. *Stat Med*. Jun 15 2004;23(11):1663-82. doi:10.1002/sim.1752
- 840 52. Hovingh GK, Kastelein JJ, van Deventer SJ, et al. Cholesterol ester transfer
841 protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised,
842 double-blind, placebo-controlled phase 2 trial. *Lancet*. Aug 01 2015;386(9992):452-60.
843 doi:10.1016/S0140-6736(15)60158-1
- 844 53. Johannsen TH, Frikke-Schmidt R, Schou J, Nordestgaard BG, Tybjaerg-
845 Hansen A. Genetic inhibition of CETP, ischemic vascular disease and mortality, and
846 possible adverse effects. *J Am Coll Cardiol*. Nov 13 2012;60(20):2041-8.
847 doi:10.1016/j.jacc.2012.07.045
- 848 54. Ference BA, Kastelein JJP, Ginsberg HN, et al. Association of Genetic
849 Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and
850 Cardiovascular Risk. *JAMA*. Sep 12 2017;318(10):947-956.
851 doi:10.1001/jama.2017.11467
- 852 55. Nordestgaard LT, Christoffersen M, Lauridsen BK, et al. Long-term Benefits
853 and Harms Associated With Genetic Cholesteryl Ester Transfer Protein Deficiency in the
854 General Population. *JAMA Cardiol*. Jan 01 2022;7(1):55-64.
855 doi:10.1001/jamacardio.2021.3728
- 856 56. Cupido AJ, Reeskamp LF, Hingorani AD, et al. Joint Genetic Inhibition of
857 PCSK9 and CETP and the Association With Coronary Artery Disease: A Factorial
858 Mendelian Randomization Study. *JAMA Cardiol*. Sep 01 2022;7(9):955-964.
859 doi:10.1001/jamacardio.2022.2333
- 860 57. Dunca D, Chopade S, Gordillo-Marañón M, et al. Comparing the effects of
861 CETP in East Asian and European ancestries: a Mendelian randomization study. Article.
862 *Nature Communications*. JUN 21 2024 2024;15(1)ARTN 5302. doi:10.1038/s41467-024-
863 49109-z
- 864 58. Wang N, Woodward M, Huffman MD, Rodgers A. Compounding Benefits of
865 Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events:
866 Systematic Review and Meta-Analysis. *Circ Cardiovasc Qual Outcomes*. Jun
867 2022;15(6):e008552. doi:10.1161/CIRCOUTCOMES.121.008552

868 59. Krishna R, Bergman AJ, Jin B, et al. Multiple-dose pharmacodynamics and
869 pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP)
870 inhibitor, in healthy subjects. *Clin Pharmacol Ther.* Dec 2008;84(6):679-83.
871 doi:10.1038/clpt.2008.109
872

(GRAPHICAL ABSTRACT)

STUDY OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITION


Low-density lipoprotein & Very-low density lipoprotein

High-density lipoprotein

Does cumulative LDL cholesterol exposure differences explain the mixed results of CETP inhibitors in cardiovascular outcomes trials?


1. Cumulative LDL exposure drives atherosclerosis risk:

Time × LDL determines reduction of cardiovascular events in clinical trials, suggesting long-term LDL reduction is key to lowering atherosclerosis risk




2. Lifelong genetic CETP inhibition reduces cardiovascular events by lowering LDL:


Life-course LDL Difference



Life-course Disease Risk



3. Mixed CETP inhibitor trial results reflect insufficient cumulative LDL lowering:



Inconsistent trial outcomes are attributable to inadequate cumulative LDL reduction, highlighting the need for more prolonged LDL lowering in future trials





Table 1. Cohort characteristics


	Complete observations (% missing)	Mean (95% CI) / No. (%)		P value
		Controls (n = 409 253)	Heterozygous <i>CETP</i> PTV carriers (n = 385)	
Age (years)	409 638 (0.0%)	56.8 (56.8-56.8)	56.7 (55.9-57.4)	0.71
Male	409 638 (0.0%)	188 542 (46.1%)	178 (46.2%)	0.96
Blood pressure (mmHg)				
Systolic	382 697 (6.6%)	139.9 (139.9-140.0)	140.8 (138.7-142.9)	0.41
Diastolic	382 708 (6.6%)	82.2 (82.2-82.2)	83.5 (82.2-84.7)	0.043
Weight (kg)	408 454 (0.3%)	78.2 (78.2-78.3)	78.1 (76.5-79.7)	0.92
BMI (kg/m ²)	408 306 (0.4%)	27.4 (27.4-27.4)	27.4 (27.0-27.9)	0.88
Self-reported diabetes status at recruitment	408 727 (0.3%)	19 783 (4.8%)	21 (5.5%)	0.55
Self-reported smoking status at recruitment	408 234 (0.4%)	42 677 (10.4%)	37 (9.6%)	0.68
Self-reported statin usage at recruitment	408 511 (0.3%)	66 879 (16.3%)	48 (12.5%)	0.039
Lipids (mmol/L)				
HDL cholesterol	357 796 (12.7%)	1.45 (1.45-1.45)	1.87 (1.81-1.92)	9 × 10 ⁻³⁷
LDL cholesterol, direct	390 187 (4.8%)	3.57 (3.57-3.57)	3.39 (3.30-3.47)	3 × 10 ⁻⁵
LDL cholesterol, Friedewald	357 486 (12.8%)	3.46 (3.46-3.47)	3.23 (3.13-3.34)	2 × 10 ⁻⁵
Non-HDL cholesterol	357 731 (12.7%)	4.26 (4.26-4.26)	4.05 (3.94-4.16)	2 × 10 ⁻⁴
Remnant cholesterol	357 145 (12.9%)	0.69 (0.69-0.69)	0.65 (0.62-0.68)	0.017
Triglycerides	390 628 (4.7%)	1.75 (1.75-1.76)	1.78 (1.67-1.90)	0.06
Lipoproteins				
Apolipoprotein B (g/L)	389 028 (5.1%)	1.04 (1.03-1.04)	0.97 (0.95-1.00)	6 × 10 ⁻⁷
Apolipoprotein A-I (g/L)	355 784 (13.2%)	1.54 (1.54-1.54)	1.73 (1.70-1.77)	6 × 10 ⁻²³
Lipoprotein(a) (nmol/L)	311 427 (24.0%)	44.0 (43.8-44.2)	37.5 (32.9-43.0)	0.021
Endpoints during follow-up				
Primary				
Any atherosclerotic disease	409 638 (0.0%)	61052 (14.9%)	39 (10.1%)	0.008
Secondary				
Coronary heart disease	409 638 (0.0%)	52666 (12.9%)	35 (9.1%)	0.027
Ischemic stroke	409 638 (0.0%)	10491 (2.6%)	6 (1.6%)	0.26
Myocardial infarction	409 631 (0.1%)	20600 (5.0%)	17 (4.4%)	0.73
Cardiovascular death	409 638 (0.0%)	4167 (1.0%)	≤5 (≤1.3%)	
Major adverse cardiovascular events	409 633 (0.1%)	29484 (7.2%)	21 (5.5%)	0.20
Peripheral atherosclerosis	409 638 (0.0%)	3667 (0.9%)	≤5 (≤1.3%)	
All-cause death	409 638 (0.0%)	36641 (9.0%)	27 (7.0%)	0.21
Any atherosclerotic disease or all-cause death	409 638 (0.0%)	83510 (20.4%)	59 (15.3%)	0.013

(FIGURE 1)

A. Cumulative LDL Cholesterol Exposure Difference when the Trajectory is Altered by Genetics



B. Cumulative LDL Cholesterol Exposure Difference when the Trajectory is Altered in a Drug Trial




$$\text{LDL-C Plaque Years Difference} = \left| \int_{t=0}^t \text{LDL-C(Exposed)} dt - \int_{t=0}^t \text{LDL-C(Not Exposed)} dt \right|$$


(FIGURE 2)

A. Survival Analysis of Atherosclerotic Events in the UK Biobank

Cumulative Events:



Event-free Survival:




No. at Risk (%)

Ctrl	408538 (100)	403397 (99)	341176 (83)	206277 (50)	39582 (10)
PTV	385 (100)	383 (99)	332 (86)	201 (52)	34 (9)


No. at Risk (%)

Ctrl	408538 (100)	403397 (99)	341176 (83)	206277 (50)	39582 (10)
PTV	385 (100)	383 (99)	332 (86)	201 (52)	34 (9)

B. Association of CETP PTVs with UK Biobank Cardiovascular Endpoints




C. Trans-Ancestry Meta-Analysis of CETP PTVs




(FIGURE 3)

ASCVD Risk Reduction vs. Interaction between LDL-C Lowering and Time of Follow-up



(FIGURE 4)

Comparison of ASCVD Risk Reduction and Cumulative LDL-C Exposure: CETP Inhibition vs. Guideline-Recommended Lipid-Lowering Therapies and LDLR PTVs




CETP Inhibition

Hazard ratio, 0.76 per 10-mmol/L × years (95% CI, 0.64–0.89)
Heterogeneity: $Q = 2.4$ (Het. P value = 0.49), $I^2 = 0\%$


Other (HMGCR, NPC1L1, PCSK9, LDLR)

Hazard ratio, 0.69 per 10-mmol/L × years (95% CI, 0.66–0.71)
Heterogeneity: $Q = 41.2$ (Het. P value = 0.11), $I^2 = 24.7\%$




(SUPPLEMENTAL FIGURE 1)

$F_{\text{Welch}}(2, 104.19) = 101.94, p = 2.97\text{e-}25, \hat{\omega}_p^2 = 0.65, \text{CI}_{95\%} [0.57, 1.00], n_{\text{obs}} = 357,794$




(SUPPLEMENTAL FIGURE 2)

Comparison of ASCVD Risk and Cumulative LDL-C Exposure: CETP Inhibition vs. Guideline-Recommended Lipid-Lowering Therapies and LDLR PTVs




Effect size & Heterogeneity

Leave-one-out effect size sensitivity analysis of statins, ezetimibe, PCSK9 inhibition, and LDLR PTVs




Leave-one-out effect size sensitivity analysis of CETP inhibition




(SUPPLEMENTAL FIGURE 4)

Comparison of ASCVD Risk and Cumulative LDL-C Exposure: CETP Inhibition vs. Guideline-Recommended Lipid-Lowering Therapies and LDLR PTVs




Effect size & Heterogeneity

Leave-one-out effect size sensitivity analysis of statins, ezetimibe, PCSK9 inhibition, and LDLR PTVs




Leave-one-out effect size sensitivity analysis of CETP inhibition



(SUPPLEMENTAL FIGURE 4)


Comparison of ASCVD Risk and Cumulative LDL-C Exposure: CETP Inhibition vs. Guideline-Recommended Lipid-Lowering Therapies and LDLR PTVs




(SUPPLEMENTAL FIGURE 7)

Effect size & Heterogeneity

Leave-one-out effect size sensitivity analysis of statins, ezetimibe, PCSK9 inhibition, and LDLR PTVs




Leave-one-out effect size sensitivity analysis of CETP inhibition




(SUPPLEMENTAL FIGURE 8)

Effect size & Heterogeneity

Leave-one-out effect size sensitivity analysis of statins, ezetimibe, PCSK9 inhibition, and LDLR PTVs





Leave-one-out effect size sensitivity analysis of CETP inhibition



(SUPPLEMENTAL FIGURE 9)




A. Meta-Regression Without Interaction Term

(Formula = Atherosclerotic Disease Risk Reduction ~ LDL-C Reduction + Time of Follow-up)



B. Meta-Regression With Interaction Term

(Formula = Atherosclerotic Disease Risk Reduction ~ LDL-C Reduction + Time of Follow-up + LDL-C Reduction × Time of Follow-up)



(SUPPLEMENTAL FIGURE 10)

A. Meta-Regression Table of Adjusted Models

SUPPLEMENTAL FIGURE 10. Meta-Regression Sensitivity Analysis					
Model	Independent variables	$\beta_{\text{LDL-C} \times \text{Follow-Up}}$	$SE_{\text{LDL-C} \times \text{Follow-Up}}$	P value	P value (Permutation)
1	LDL-C Reduction, Time of Follow-Up, LDL-C Reduction \times Time of Follow-Up	-0.0378	0.0131	0.0074	0.0090
2	1 + Baseline LDL-C	-0.0343	0.0131	0.0136	0.0180
3	1 + Annualized ASCVD event risk	-0.0384	0.0161	0.0236	0.0290
4	1 + Cumulative ASCVD event risk	-0.0361	0.0133	0.0113	0.0110
5	1 + Mean Age at Baseline	-0.0327	0.0128	0.0164	0.0250
6	1 + Year published	-0.0356	0.0125	0.0079	0.0060

B. Multi-Model Inference Analysis

